```html

Zollinger‑Ellison Syndrome (Gastrinoma): A Comprehensive Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by one or more gastrin‑producing tumors (gastrinomas) that arise in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which stimulates the stomach lining to produce large volumes of acidic gastric juice. The resulting hyperacidity leads to severe peptic ulcer disease, diarrhea, and other gastrointestinal problems.

Who it affects: ZES can occur at any age but most commonly presents in the fourth to sixth decades of life. Both men and women are affected, with a slight male predominance (≈55% of cases). Around 20–30% of patients have an inherited form linked to multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are rare, with an estimated incidence of 0.5–2 cases per million people per year. ZES accounts for roughly 0.5% of all duodenal or pancreatic neuroendocrine tumors.<sup>[1] Mayo Clinic</sup> Because symptoms mimic common ulcers, the condition is often diagnosed after years of unexplained gastrointestinal complaints.

Symptoms

The clinical picture varies depending on tumor size, location, and the amount of gastrin produced. Common symptoms include:

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunum).
• Abdominal pain – usually burning or cramping, worsens with meals.
• Diarrhea – watery, may be chronic; caused by acid inactivation of pancreatic enzymes and damage to intestinal mucosa.
• Steatorrhea (fatty stools) – malabsorption from pancreatic enzyme inactivation.
• Nausea & vomiting – especially after meals.
• Weight loss – due to malabsorption and decreased appetite.
• Gastroesophageal reflux disease (GERD) – heartburn from excessive acid.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Fatigue & anemia – chronic blood loss.
• Gastroparesis – delayed stomach emptying in some patients.

When gastrinomas are part of MEN‑1, patients may also have signs of other endocrine tumors (parathyroid hyperplasia, pituitary adenomas).

Causes and Risk Factors

Underlying cause

ZES is caused by gastrin‑secreting neuroendocrine tumors. These tumors arise from enterochromaffin‑like (ECL) cells in the duodenum or pancreas. Most gastrinomas are sporadic, but about 20–30% are linked to the hereditary syndrome MEN‑1, caused by mutations in the MEN1 tumor‑suppressor gene.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Genetic mutations – germline MEN1 or CDC73 mutations.
• Age – most cases diagnosed between 40–60 years.
• Previous gastric ulcer disease – not a cause, but often precedes diagnosis.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential. Diagnosis involves biochemical, imaging, and endoscopic studies.

1. Biochemical tests

• Fasting serum gastrin level – a level >1000 pg/mL (10 ng/L) is highly suggestive, especially when gastric pH <2.0.<sup>[2] NIH</sup>
• Secretin stimulation test – paradoxical rise in gastrin after intravenous secretin (increase ≥120 pg/mL) confirms ZES when basal gastrin is equivocal.
• Gastric pH measurement – low pH (≤2) supports hyperacidity.

2. Imaging studies

• Endoscopic ultrasound (EUS) – excellent for locating small (<2 cm) pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – helps assess tumor size, local invasion, and metastases (especially liver).
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – detects neuroendocrine tumors expressing somatostatin receptors; most sensitive for metastatic disease.

3. Endoscopic evaluation

• Upper endoscopy (EGD) – visualizes ulcers, biopsies for H. pylori (to rule out other causes), and may guide therapeutic interventions.

4. Histopathology

If surgical resection is performed, pathology confirms a well‑differentiated neuroendocrine tumor, typically staining positive for gastrin and chromogranin A.

Treatment Options

Management targets two goals: control of gastric acid hypersecretion and removal or control of the tumor. Treatment is individualized based on tumor size, location, presence of metastasis, and patient health.

1. Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs) – high‑dose omeprazole 60–120 mg daily, esomeprazole 40–80 mg, or rabeprazole 40 mg. PPIs are the cornerstone; they normalize gastric pH, heal ulcers, and relieve diarrhea.
• H2‑receptor antagonists (e.g., ranitidine) – less effective than PPIs and generally used only if PPIs are contraindicated.

Long‑term PPI use requires monitoring for vitamin B12 deficiency, magnesium loss, and bone health.<sup>[3] Cleveland Clinic</sup>

2. Surgical management

• Curative resection – enucleation or segmental pancreatectomy for localized tumors; associated with 5‑year disease‑free survival >80% when disease is confined.
• Debulking surgery – for metastatic disease to reduce tumor burden and gastrin production.
• Liver metastasectomy – indicated when hepatic lesions are resectable.

3. Medical therapies for unresectable or metastatic disease

• Somatostatin analogs (octreotide, lanreotide) – inhibit gastrin release and may shrink tumors.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival.
• Chemotherapy – reserved for high‑grade, poorly differentiated gastrinomas.

4. Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce gastric irritation.
• Avoidance of alcohol, nicotine, and NSAIDs, which aggravate ulcer disease.
• Supplementation of calcium, vitamin D, and magnesium if on long‑term PPIs.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; do not skip doses.
• Monitor symptoms – keep a diary of abdominal pain, stool changes, and any signs of bleeding.
• Regular follow‑up – quarterly labs (fasting gastrin, calcium, liver function) and annual imaging to detect recurrence.
• Nutrition – work with a dietitian to ensure adequate caloric intake; consider enzyme supplements if steatorrhea persists.
• Vaccinations – stay up to date on hepatitis B and pneumococcal vaccines, especially if liver metastases are present.
• Stress management – chronic disease can affect mental health; counseling or support groups are beneficial.

Psychosocial considerations

Living with a rare, chronic condition can be isolating. Connecting with patient advocacy groups such as the Neuroendocrine Tumor Patient Foundation (NET-PF) provides education and emotional support.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• For individuals with a known MEN‑1 mutation: annual biochemical screening (fasting gastrin) and imaging starting in adolescence, as recommended by the American Association of Clinical Endocrinologists.<sup>[4] AACE</sup>
• Avoid chronic use of medications that increase gastric acid (e.g., long‑term H2 blockers without PPI coverage) – though evidence is modest.
• Prompt treatment of H. pylori infection and avoidance of smoking to reduce overall ulcer burden.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory peptic ulcer disease – increased risk of perforation and peritonitis.
• Upper gastrointestinal bleeding – may require endoscopic therapy or surgery.
• Gastrointestinal obstruction – from scarring or tumor mass effect.
• Malabsorption & severe weight loss – leading to nutritional deficiencies.
• Metastatic disease – liver is the most common site; 60–80% of gastrinomas present with metastases at diagnosis.
• MEN‑1 associated endocrine dysfunctions – hyperparathyroidism, pituitary adenomas.
• Rare malignancy – poorly differentiated gastrinomas can behave aggressively.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org/…
2. National Institutes of Health (NIH). “Gastrinoma (Zollinger‑Ellison syndrome).” 2022. https://rarediseases.info.nih.gov/…
3. Cleveland Clinic. “Long‑term proton pump inhibitor use: Risks and benefits.” 2021. https://my.clevelandclinic.org/…
4. American Association of Clinical Endocrinology (AACE). “Guidelines for the Management of MEN‑1.” 2020. https://www.aace.com/…
5. World Health Organization. “Neuroendocrine Tumors: A Global Perspective.” 2022.

```